Top Suppliers:I want be here
Related CAS#:
1517846-25-1 1521833-48-6
1499992-52-7 397846-50-3
1808738-15-9 1506459-11-5
1499342-36-7 1270179-50-4
1520782-48-2 1535448-85-1

64790-15-4

64790-15-4 structure
64790-15-4 structure
  • Name: Glucagon (19-29) (human, rat, porcine) trifluoroacetate salt
  • Chemical Name: h-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr-oh
  • CAS Number: 64790-15-4
  • Molecular Formula: C61H89N15O18S
  • Molecular Weight: 1352.51000
  • Catalog: Peptides
  • Create Date: 2018-10-19 22:06:14
  • Modify Date: 2024-01-02 20:01:24
  • Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
Name h-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr-oh
Synonyms Miniglucagon (huMan,rat,porcine)
Glucagon (19-29) (human,rat,porcine)
GLUCAGON (19-29),HUMAN
AQDFVQWLMNT
glucagon(19-29
Glucagon (19-29) (huMan,rat,porcine) Miniglucagon (huMan,rat,porcine)
ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR
GLUCAGON (19-29),BOVINE,HUMAN,PORCINE
GLUCAGON (19-29) (HUMAN,BOVINE,PORCINE)
Glucagon (19-29), human
Description Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
Related Catalog
Target

Insulin secretion[1]

In Vitro Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29)[3].
In Vivo Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein[2].
Animal Admin Rats[1] To test the effect of miniglucagon (Glucagon (19-29)) on stimulated insulin secretion, 8.3 mM glucose is perfused during the experiments, including a 45-min equilibration period, followed by miniglucagon (1, 10, 100, and 1,000 pM) perfused with or without 1 nM tGLP-1. To study the glucagon and miniglucagon secretion, the glucose concentration is switched from 11 to 3 mM after a 45-min stabilization period, and the peptides secreted are measured by radioimmunoassay[1].
References

[1]. Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76.

[2]. Dalle S, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12.

[3]. Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9.
Density 1.339 g/cm3
Boiling Point 1828.5ºC at 760 mmHg
Molecular Formula C61H89N15O18S
Molecular Weight 1352.51000
Flash Point 1059.6ºC
Exact Mass 1351.62000
PSA 582.21000
LogP 2.66020
Index of Refraction 1.596

Chemsrc provides CAS#:64790-15-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 64790-15-4 | Chemsrc address: https://m.chemsrc.com/en/baike/337477.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved